SUCRAID
LOE Approachingsacrosidase
BLAORALSOLUTIONPriority Review
Approved
Apr 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SUCRAID (sacrosidase) is an oral enzyme replacement therapy approved in 1998 for the treatment of congenital sucrase-isomaltase deficiency (CSID), a rare inherited disorder affecting the ability to digest sucrose. The drug is a sucrose-specific enzyme that replaces the missing or deficient enzyme in patients who cannot break down table sugar, allowing improved carbohydrate digestion and reducing gastrointestinal symptoms.
$77MPart D
LOE ApproachingThe product is approaching loss of exclusivity with modest Part D spending ($77M) and a small claim volume (6,130 claims in 2023), indicating a niche rare disease asset with limited commercial growth potential and likely a small, specialized team.
Mechanism of Action
Pharmacologic Class:
Sucrose-specific Enzyme
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Effects of Sacrosidase and Placebo in Subjects With Fructan Intolerance
Started Jun 2023
25 enrolled
Fructan Intolerance
7-Day Trial of Sucraid for Alleviating CSID Symptoms in Subjects With Low, Moderate, and Normal Sucrase Levels
Started Aug 2022
312 enrolled
Congenital Sucrase-Isomaltase DeficiencyCSIDSucrase Isomaltase Deficiency
A Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Safety of Sucraid® (Sacrosidase) Oral Solution in Subjects With Chronic Diarrhea and Sucrase Deficiency
Started May 2016
0Genetic Sucrase-Isomaltase Deficiency
Career Relevance
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.